- Home
- PIII vs HCWB Comparison
PIII vs HCWB Comparison
Compare PIII & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- HCWB
- Stock Information
- Founded
- PIII 2015
- HCWB 2018
- Country
- PIII United States
- HCWB United States
- Employees
- PIII N/A
- HCWB N/A
- Industry
- PIII Medical/Nursing Services
- HCWB Biotechnology: Pharmaceutical Preparations
- Sector
- PIII Health Care
- HCWB Health Care
- Exchange
- PIII Nasdaq
- HCWB Nasdaq
- Market Cap
- PIII 32.2M
- HCWB 26.6M
- IPO Year
- PIII N/A
- HCWB 2021
- Fundamental
- Price
- PIII $0.20
- HCWB $0.45
- Analyst Decision
- PIII Buy
- HCWB
- Analyst Count
- PIII 3
- HCWB 0
- Target Price
- PIII $2.38
- HCWB N/A
- AVG Volume (30 Days)
- PIII 347.2K
- HCWB 652.7K
- Earning Date
- PIII 11-12-2024
- HCWB 11-14-2024
- Dividend Yield
- PIII N/A
- HCWB N/A
- EPS Growth
- PIII N/A
- HCWB N/A
- EPS
- PIII N/A
- HCWB N/A
- Revenue
- PIII $1,476,630,000.00
- HCWB $3,495,990.00
- Revenue This Year
- PIII $21.45
- HCWB $229.19
- Revenue Next Year
- PIII N/A
- HCWB N/A
- P/E Ratio
- PIII N/A
- HCWB N/A
- Revenue Growth
- PIII 25.38
- HCWB 22.27
- 52 Week Low
- PIII $0.18
- HCWB $0.28
- 52 Week High
- PIII $1.78
- HCWB $2.52
- Technical
- Relative Strength Index (RSI)
- PIII 35.62
- HCWB 49.33
- Support Level
- PIII $0.22
- HCWB $0.32
- Resistance Level
- PIII $0.23
- HCWB $0.43
- Average True Range (ATR)
- PIII 0.02
- HCWB 0.05
- MACD
- PIII 0.00
- HCWB -0.00
- Stochastic Oscillator
- PIII 26.62
- HCWB 67.89
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.